| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$1,435,800 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
3,704 |
4,538 |
27,327 |
202,315 |
| Total Sell Value |
$438,449 |
$537,921 |
$3,641,323 |
$29,586,917 |
| Total People Sold |
1 |
3 |
13 |
19 |
| Total Sell Transactions |
2 |
4 |
21 |
79 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Riedel Norbert G |
Director |
– • – |
2021-08-06 |
4 |
S |
$147.96 |
$193,236 |
D/D |
(1,306) |
10,399 |
|
- |
|
| Gray Peter |
Director |
– • – |
2021-08-06 |
4 |
S |
$147.96 |
$209,215 |
D/D |
(1,414) |
12,852 |
|
- |
|
| Carr Patricia |
SVP, Finance & PAO |
• – – |
2021-08-06 |
4 |
S |
$147.96 |
$23,230 |
D/D |
(157) |
6,035 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2021-08-06 |
4 |
S |
$147.96 |
$193,236 |
D/D |
(1,306) |
19,607 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2021-08-06 |
4 |
S |
$147.96 |
$193,236 |
D/D |
(1,306) |
11,562 |
|
- |
|
| Schnee Elmar |
Director |
– • – |
2021-08-05 |
4 |
S |
$154.00 |
$251,328 |
D/D |
(1,632) |
8,270 |
|
- |
|
| Patil Neena M |
CLO&SVP Legal and Corp Affairs |
• – – |
2021-08-05 |
4 |
D |
$148.49 |
$147,451 |
D/D |
(993) |
25,233 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2021-08-05 |
4 |
OE |
$46.83 |
$124,193 |
D/D |
2,652 |
309,790 |
|
- |
|
| Berns Paul L |
Director |
– • – |
2021-08-05 |
4 |
S |
$154.00 |
$223,300 |
D/D |
(1,450) |
8,290 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2021-08-02 |
4 |
AS |
$169.98 |
$297,470 |
D/D |
(1,750) |
307,138 |
|
- |
|
| Mcsharry Heather Ann |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,246 |
12,579 |
|
- |
|
| Winningham Rick E |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,246 |
8,444 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,246 |
1,157,739 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,246 |
12,868 |
|
- |
|
| Gray Peter |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,246 |
14,266 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,246 |
20,913 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,246 |
11,705 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,246 |
22,614 |
|
- |
|
| Smith Mark Douglas |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,246 |
4,836 |
|
- |
|
| Oriordan Anne |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,246 |
9,711 |
|
- |
|
| Cook Jennifer E. |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,246 |
4,836 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2021-07-01 |
4 |
AS |
$180.67 |
$1,960,270 |
D/D |
(10,850) |
308,888 |
|
- |
|
| Iannone Robert |
EVP R&D, Chief Medical Officer |
• – – |
2021-06-05 |
4 |
D |
$176.47 |
$212,823 |
D/D |
(1,206) |
29,086 |
|
- |
|
| Sablich Kim |
EVP & GM, North America |
• – – |
2021-06-05 |
4 |
D |
$176.47 |
$256,234 |
D/D |
(1,452) |
23,883 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2021-06-01 |
4 |
AS |
$179.07 |
$313,373 |
D/D |
(1,750) |
319,738 |
|
- |
|
881 Records found
|
|
Page 10 of 36 |
|
|
0.37 (0.34%) 
